Silke C Hofmann

Dr. Silke C Hofmann


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
PJP. Joly
P. Joly
BHB. Horvath
B. Horvath
ΑPΑ Patsatsi
Α Patsatsi
SUS. Uzun
S. Uzun
RBR. Bech
R. Bech
ESE. Schmidt
E. Schmidt

25 March 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
EAEmiliano Antiga
Emiliano Antiga
RBRikke Bech
Rikke Bech
RMRoberto Maglie
Roberto Maglie
GGGiovanni Genovese
Giovanni Genovese
LBLuca Borradori
Luca Borradori
Angelo MarzanoAngelo Marzano
Angelo Marzano
Background: Paraneoplastic pemphigus (PNP), also called paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare autoimmune disease with mucocutaneous and multi‐organ involvement. PNP/PAMS is typically associated with lymphoproliferative or haematological malignancies, and less frequently with solid malignancies. The mortality rate of PNP/PAMS is elevated owing to the increased risk of severe infections and disease‐associated complications, such as bronchiolitis obliterans.Objectives: These guidelines summarize evidence‐based and expert‐based recommendations (S2k level) for the clinical characterization, diagnosis and management of PNP/PAMS. They have been initiated by the Task Force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology with the contribution of physicians from all relevant disciplines. The degree of consent among all task force members was included.Results: Chronic severe mucositis and polymorphic skin lesions are clue clinical characteristics of PNP/PAMS. A complete assessment of the patient with suspected PNP/PAMS, requiring histopathological study and immunopathological investigations, including direct and indirect immunofluorescence, ELISA and, where available, immunoblotting/immunoprecipitation, is recommended to achieve a diagnosis of PNP/PAMS. Detection of anti‐envoplakin antibodies and/or circulating antibodies binding to the rat bladder epithelium at indirect immunofluorescence is the most specific tool for the diagnosis of PNP/PAMS in a patient with compatible clinical and anamnestic features. Treatment of PNP/PAMS is highly challenging. Systemic steroids up to 1.5 mg/kg/day are recommended as first‐line option. Rituximab is also recommended in patients with PNP/PAMS secondary to lymphoproliferative conditions but might also be considered in cases of PNP/PAMS associated with solid tumours. A multidisciplinary approach involving pneumologists, ophthalmologists and onco‐haematologists is recommended for optimal management of the patients.Conclusions: These are the first European guidelines for the diagnosis and management of PNP/PAMS. Diagnostic criteria and therapeutic recommendations will require further validation by prospective studies.

29 February 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
FCFrédéric Caux
Frédéric Caux
APAikaterini Patsatsi
Aikaterini Patsatsi
MKMeropi Karakioulaki
Meropi Karakioulaki
EAEmiliano Antiga
Emiliano Antiga
EBEulalia Baselga
Eulalia Baselga
ESEnno Schmidt
Enno Schmidt
Introduction: Linear IgA dermatosis (LAD) is a rare subepidermal autoimmune bullous disease (AIBD) defined by predominant or exclusive immune deposits of immunoglobulin A at the basement membrane zone of skin or mucous membranes. This disorder is a rare, clinically and immunologically heterogeneous disease occurring both in children and in adults. The aim of this project is to present the main clinical features of LAD, to propose a diagnostic algorithm and provide management guidelines based primarily on experts' opinion because of the lack of large methodologically sound clinical studies.Methods: These guidelines were initiated by the European Academy of Dermatology and Venereology (EADV) Task Force Autoimmune Bullous Diseases (AIBD). To achieve a broad consensus for these S2k consensus‐based guidelines, a total of 29 experts from different countries, both European and non‐European, including dermatologists, paediatric dermatologists and paediatricians were invited. All members of the guidelines committee agreed to develop consensus‐based (S2k) guidelines. Prior to a first virtual consensus meeting, each of the invited authors elaborated a section of the present guidelines focusing on a selected topic, based on the relevant literature. All drafts were circulated among members of the writing group, and recommendations were discussed and voted during two hybrid consensus meetings.Results: The guidelines summarizes evidence‐based and expert opinion‐based recommendations (S2 level) on the diagnosis and treatment of LAD.Conclusion: These guidelines will support dermatologists to improve their knowledge on the diagnosis and management of LAD.

1 July 2013 in Journal of Dermatological Science
Verified
Journal Article
Closed access
SHSilke C Hofmann
Silke C Hofmann
ABAnneleen Bosma
Anneleen Bosma
LBLeena Bruckner-Tuderman
Leena Bruckner-Tuderman
MVMilica Vukmanovic-Stejic
Milica Vukmanovic-Stejic
Elizabeth C JuryElizabeth C Jury
Elizabeth C Jury
CMClaudia Mauri
Claudia Mauri

3 September 2024 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
GBGalina Balakirski
Galina Balakirski
PLPercy Lehmann
Percy Lehmann
RSRolf‐Markus Szeimies
Rolf‐Markus Szeimies
SHSilke C Hofmann
Silke C Hofmann
Summary: Photodynamic therapy (PDT) is internationally established as an approved treatment option for in situ forms of keratinocytic skin cancer (actinic keratoses, Bowen's disease, basal cell carcinoma). For these indications, there are standardized treatment protocols using narrow‐spectrum light sources or (artificial) daylight, the use of which is associated with successful healing, a low rate of lesion recurrence, and a very good cosmetic result.Daylight PDT is superior to conventional PDT in terms of significantly less pain and associated higher patient acceptance.Newer indications, for which no approval has yet been granted, but which nevertheless have sufficient evidence of efficacy according to the study situation, are inflammatory (lichen sclerosus, acne) and infectious dermatoses (viral warts, cutaneous leishmaniasis, atypical mycobacteriosis). In addition, PDT is increasingly being used in aesthetic dermatology with the aim of skin rejuvenation.

30 June 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
GBG. Balakirski
G. Balakirski
AMA.‐L. Michalowitz
A.‐L. Michalowitz
AKA. Kreuter
A. Kreuter
SHSilke C Hofmann
Silke C Hofmann